Serhat Sekmek

19PUBLICATIONS
144CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Foetal development and medicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Jul 28, 2026
Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy.

|Jul 15, 2026
Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study.

|Jun 16, 2026
Low muscle mass predicts poor response to neoadjuvant chemotherapy in advanced ovarian cancer.

|Mar 28, 2026
Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG).

Bengü Dursun, Şendağ Yaslıkaya, Serhat Sekmek

|Mar 23, 2026
Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study.

Osman Sütcüoğlu, Orhun Akdoğan, İlknur Deliktaş Onur

|Jan 29, 2026
Prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer: a retrospective cohort study.

Furkan Ceylan, Serhat Sekmek, Ateş Kutay Tenekeci

Pageof 4

Frequent Collaborators

7 joint publications

Dogan Bayram

3 joint publications

Perihan Perkin

3 joint publications

Fahriye Tugba Kos

3 joint publications

Öznur Bal